公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
1999 | Bacterial infections associated with hepatic arteriography and transarterial embolization for hepatocellular carcinoma: A prospective study | Chen C.; Tsang Y.-M.; PO-REN HSUEH ; GUAN-TARN HUANG ; PEI-MING YANG ; JIN-CHUAN SHEU ; Lai M.-Y.; PEI-JER CHEN ; DING-SHINN CHEN | Clinical Infectious Diseases | 31 | 21 | |
2003 | Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers | JIA-HORNG KAO ; PEI-JER CHEN ; Lai M.-Y.; DING-SHINN CHEN | Gastroenterology | 491 | 437 | |
2005 | Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B | Lin C.-L.; Liao L.-Y.; Wang C.-S.; PEI-JER CHEN ; Lai M.-Y.; DING-SHINN CHEN ; JIA-HORNG KAO | Liver International | 72 | 64 | |
2019 | Baseline Level of Hepatitis B Core Antibody Predicts Spontaneous Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Children With a Normal Alanine Aminotransferase Level | HO-SHENG CHEN ; JIA-FENG WU ; TUNG-HUNG SU ; HUEY-LING CHEN ; HONG-YUAN HSU ; Xia N.-S.; PEI-JER CHEN ; MEI-HWEI CHANG | Hepatology | 16 | 9 | |
2020 | Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy | TAI-CHUNG TSENG ; Peng C.-Y; Hsu Y.-C; TUNG-HUNG SU ; Wang C.-C; CHUN-JEN LIU ; HUNG-CHIH YANG ; Yang W.-T; Lin C.-H; Yu M.-L; Lai H.-C; Tanaka Y; Nguyen M.H; CHEN-HUA LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Liver Cancer | 17 | 13 | |
1997 | Benign recurrent intrahepatic cholestasis | CHUN-JEN LIU ; JIA-HORNG KAO ; PEI-JER CHEN ; Lai M.-Y.; TSUI-LIEN MAO ; Wang T.-H.; DING-SHINN CHEN | Journal of the Formosan Medical Association | 1 | 0 | |
2012 | Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity | Chen K.-F.; Tai W.-T.; Hsu C.-Y.; Huang J.-W.; Liu C.-Y.; PEI-JER CHEN ; Kim I.; Shiau C.-W. | European Journal of Medicinal Chemistry | 72 | 70 | |
1997 | Blood-bank screening for hepatitis G [14] | JIA-HORNG KAO ; PEI-JER CHEN ; JIN-TOWN WANG ; Lai M.-Y.; DING-SHINN CHEN | Lancet | 7 | 5 | |
2018 | Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan | Hsieh M.-H.; Yeh M.-L.; TUNG-HUNG SU ; Liu T.-W.; Huang C.-F.; Huang C.-I.; Wang S.-C.; Huang J.-F.; Dai C.-Y.; JIA-HORNG KAO ; Chuang W.-L.; PEI-JER CHEN ; CHUN-JEN LIU ; Yu M.-L. | Journal of the Formosan Medical Association | 5 | 4 | |
2024 | Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B | Cheng, Pin-Nan; Feng, I-Cher; Chen, Jyh-Jou; Kuo, Hsing-Tao; Lee, Pei-Lun; Yu, Ming-Lung; Chiu, Yen-Cheng; Chiu, Hung-Chih; Chien, Shih-Chieh; PEI-JER CHEN ; CHUN-JEN LIU | Alimentary pharmacology & therapeutics | 2 | 0 | |
2009 | Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway | Chen K.-F.; Yeh P.-Y.; CHIUN HSU ; CHIH-HUNG HSU ; YEN-SHEN LU ; Hsieh H.-P.; PEI-JER CHEN ; ANN-LII CHENG | Journal of Biological Chemistry | 89 | 84 | |
2011 | Bortezomib sensitizes HCC cells to CS-1008, an antihuman death receptor 5 antibody, through the inhibition of CIP2A | Chen K.-F.; Yu H.-C.; Liu C.-Y.; Chen H.-J.; Chen Y.-C.; Hou D.-R.; PEI-JER CHEN ; ANN-LII CHENG | Molecular Cancer Therapeutics | 36 | 32 | |
1998 | Brief communication: Efficacy of ribavirin plus interferon α on viraemia of GB virus-C/hepatitis G virus: Comparison with interferon α alone | JIA-HORNG KAO ; Lai M.-Y.; Chen W.; PEI-JER CHEN ; DING-SHINN CHEN | Journal of Gastroenterology and Hepatology (Australia) | 10 | 10 | |
2011 | Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan | PEI-JER CHEN ; Lin J.-J.; Lu C.-S.; Ong C.-T.; Hsieh P.F.; Yang C.-C.; Tai C.-T.; Wu S.-L.; Lu C.-H.; Hsu Y.-C.; Yu H.-Y.; Ro L.-S.; Lu C.-T.; Chu C.-C.; Tsai J.-J.; Su Y.-H.; Lan S.-H.; Sung S.-F.; Lin S.-Y.; Chuang H.-P.; Huang L.-C.; Chen Y.-J.; Tsai P.-J.; Liao H.-T.; Lin Y.-H.; Chen C.-H.; Chung W.-H.; Hung S.-I.; Wu J.-Y.; Chang C.-F.; Chen L.; Chen Y.-T.; Shen C.-Y. | New England Journal of Medicine | 578 | 496 | |
1996 | Casein kinase II and protein kinase C modulate hepatitis delta virus RNA replication but not empty viral particle assembly | Yeh T.-S.; Lo S.J.; PEI-JER CHEN ; Lee Y.-H.W. | Journal of Virology | 40 | 39 | |
2019 | Cell and Animal Models for Studying Hepatitis B Virus Infection and Drug Development | Hu J.; Lin Y.-Y.; PEI-JER CHEN ; Watashi K.; Wakita T. | Gastroenterology | 66 | 68 | |
2020 | Cell-Free Virus-Host Chimera DNA From Hepatitis B Virus Integration Sites as a Circulating Biomarker of Hepatocellular Cancer | Li C.-L.; MING-CHIH HO ; Lin Y.-Y.; Tzeng S.-T.; Chen Y.-J.; Pai H.-Y.; Wang Y.-C.; CHI-LING CHEN ; Lee Y.-H.; Chen D.-S.; Shiou-Hwei Yeh ; PEI-JER CHEN | Hepatology | 30 | 24 | |
1992 | Cellular Immune Response to HBcAg in Mother‐to‐Infant Transmission of Hepatitis B Virus | HONG-YUAN HSU ; MEI-HWEI CHANG ; Hsieh K. H.; CHIN-YUN LEE ; HO-HSIUNG LIN ; Hwang L. H.; PEI-JER CHEN ; DING-SHINN CHEN | Hepatology | 113 | 94 | |
2024 | Challenges for hepatitis B control in Asia-Pacific areas: Consolidating vaccination and rolling-out antiviral therapies | PEI-JER CHEN | Journal of gastroenterology and hepatology | | | |
1990 | Changes of serum hepatitis B virus DNA and aminotransferase levels during the course of chronic hepatitis B virus infection in children | PING-ING LEE ; MEI-HWEI CHANG ; CHIN-YUN LEE ; HONG-YUAN HSU ; Chen J.-S.; PEI-JER CHEN ; DING-SHINN CHEN | Hepatology | | | |